Peptide Initiative

Peptide profile · Immune

Gramicidin

Historic 15-amino-acid linear pentadecapeptide antibiotic with alternating D- and L-amino acids — the first commercially produced antibiotic discovered by René Dubos in 1939, forming monovalent cation-selective transmembrane channels in bacterial membranes, FDA-approved as a topical/ophthalmic antimicrobial component of Neosporin and related preparations

Strong human trialsFDA approved for this use
Local tissue persistence: hours to days at topical application sitesHalf-life (protease-resistant D-amino acid structure); systemic half-life: not applicable (hemolytic — never administered systemically); single channel lifetime: ~1 second (open/close kinetics in electrophysiology)
Topical: local tissue concentrations at application site; systemic absorption negligible through intact skin and eye; oral bioavailability: not applicableBioavailability (not used orally for systemic effect; would cause GI hemolysis); intrinsically resistant to proteases due to D-amino acid content
1,882.3 DaMolecular weight (gramicidin A); Gramicidin D mixture: ~1,880-1,900 Da average

Molecular formula

C₉₉H₁₄₀N₂₀O₁₇ (gramicidin A)

CAS number
11029-61-1 (gramicidin A); 1405-97-6 (gramicidin D mixture)
PubChem
16132269 (gramicidin A); 45267103 (gramicidin D)
Developed · 1939 (discovery by Dubos); 1941 (first clinical testing); FDA-approved as topical/ophthalmic antimicrobial component
René Dubos and Rollin Hotchkiss, Rockefeller Institute for Medical Research, New York

Amino acid sequence

Gramicidin A: HCO-L-Val-Gly-L-Ala-D-Leu-L-Ala-D-Val-L-Val-D-Val-L-Trp-D-Leu-L-Trp-D-Leu-L-Trp-D-Leu-L-Trp-NHCH₂CH₂OH (15 AA, alternating D,L-configuration, formylated N-terminus, ethanolamine C-terminus, 4 tryptophan residues)

Bacterial Infection TreatmentGramicidin kills harmful bacteria on skin and eyes within seconds by punching tiny holes in their outer walls.

9.5

Eye Infection CareFDA-approved for treating pink eye and other bacterial eye infections when combined with other antibiotics in prescription drops .

9.2

Wound ProtectionFound in over-the-counter antibiotic ointments to help prevent infection in minor cuts, scrapes, and burns.

8.8

Ratings out of 10.

0.025mg

Every documented dose level

PhaseDoseFrequency
Days 7-10Gramicidin 0.025 mg/mL (in neomycin/polymyxin B/gramicidin ophthalmic solution); instill 1-2 dropsEvery 4 hours (up to 2 drops every hour for severe infection)
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for topical treatment of bacterial conjunctivitis and external eye infections (fda-approved) & prophylaxis and treatment of superficial skin infections, minor cuts, scrapes, and burns (otc topical preparations)

Best for

  • Topical treatment of bacterial conjunctivitis and external eye infections (FDA-approved)

    Gramicidin is particularly well-suited for individuals focused on topical treatment of bacterial conjunctivitis and external eye infections (fda-approved). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Prophylaxis and treatment of superficial skin infections, minor cuts, scrapes, and burns (OTC topical preparations)

    Gramicidin is particularly well-suited for individuals focused on prophylaxis and treatment of superficial skin infections, minor cuts, scrapes, and burns (otc topical preparations). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Research into ion channel biophysics, single-channel electrophysiology, and membrane transport mechanisms

    Gramicidin is particularly well-suited for individuals focused on research into ion channel biophysics, single-channel electrophysiology, and membrane transport mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Combination topical antimicrobial therapy providing Gram-positive coverage alongside polymyxin B for Gram-negatives

    Gramicidin is particularly well-suited for individuals focused on combination topical antimicrobial therapy providing gram-positive coverage alongside polymyxin b for gram-negatives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

Consider alternatives if

Alternative approaches for immune supportConsult your healthcare provider for alternatives to Gramicidin based on your specific needs and medical history
Alternative immune-modulating peptidesThymosin Alpha-1LL-37Thymulin
Non-peptide immune supportVitamin D3Zinc supplementationBeta-glucans

Do not use if

  • Known hypersensitivity to gramicidin or any component of topical/ophthalmic formulations
  • Systemic administration by any route — gramicidin is hemolytic and toxic to red blood cells; strictly topical/ophthalmic use only
  • Deep puncture wounds or severe burns requiring systemic antimicrobial coverage
  • Prolonged use on large open wounds — even topical gramicidin may cause hemolysis if absorbed systemically through extensive denuded skin

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Gramicidin use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Gramicidin with similar peptides to find the best fit for your goals.

Route

Gramicidin is administered Topical application (primary clinical route)—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Gramicidin dosing protocol covers how it is taken.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Gramicidin is a cyclic peptide antibiotic derived from Bacillus brevis with a 70+ year track record of topical safety.

It functions as a pore-former in bacterial membranes and shows minimal systemic absorption when applied to intact skin or mucous membranes, making it extremely low-toxicity for localized use.

The primary safety concern is sensitization reactions in 1-5% of users with prolonged exposure, not organ toxicity. Gramicidin is FDA-approved for topical antibacterial applications and generally well-tolerated across age groups.

Gramicidin safety derives from extensive clinical use since 1940s as a topical antibiotic in wound care and oral preparations, with minimal adverse event reporting.

In vitro studies confirm rapid bacterial cell death via ion channel disruption without mammalian toxicity at therapeutic concentrations. Contact dermatitis and allergic sensitization are the documented safety signals, not systemic toxicity.

FDA oversight and decades of post-marketing surveillance support its continued use in medical devices and antimicrobial formulations.


Common side effects · experienced by some users

Ophthalmic stinging/burning

Mild stinging or burning sensation upon instillation of ophthalmic drops, lasting 1-2 minutes. Common with most antibiotic eye drops.

Management
Self-limiting. Keep eyes closed for 1-2 minutes after application. If persistent, discontinue and consult ophthalmologist.

Local skin irritation

Mild redness or warmth at the topical application site. Common with antibiotic ointments and usually minor.

Management
Apply thin layer only. If irritation worsens, discontinue and try alternative topical antibiotic.

Temporary blurred vision

Brief visual blurring after application of ophthalmic ointment due to the ointment base coating the eye surface.

Management
Expected with ointment formulations. Vision clears within 5-10 minutes. Use drops instead of ointment during daytime if vision clarity is important.

Contact sensitization

Allergic contact dermatitis may develop with prolonged or repeated topical use, manifesting as increased redness, itching, or vesicle formation at the application site.

Management
Discontinue gramicidin-containing products. Topical corticosteroid for acute dermatitis. Patch testing may identify specific allergen if multiple antibiotic sensitivities.

Serious side effects

Hemolytic toxicity with systemic absorption

Gramicidin is hemolytic — it forms ion channels in red blood cell membranes causing hemolysis. This occurs only if significant systemic absorption happens through extensive wound application or mucous membrane exposure. This is why gramicidin is restricted to topical use.

Management
NEVER administer gramicidin systemically (IV, IM, oral for systemic effect). Avoid application to large denuded skin areas. If accidental systemic exposure occurs, monitor for hemolysis and provide supportive care.

Less commonSuperinfection

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Gramicidin
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Gramicidin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafePolymyxin B (complementary spectrum — gramicidin covers Gram-positives, polymyxin B covers Gram-negatives; this is the basis of Neosporin ophthalmic formulation) — May be used together under medical guidance.
  • SafeNeomycin (aminoglycoside — provides additional Gram-negative and some Gram-positive coverage; standard triple combination in OTC antibiotic ointments) — May be used together under medical guidance.
  • SafeBacitracin (complementary Gram-positive coverage through peptidoglycan synthesis inhibition — different mechanism than gramicidin's ion channels) — May be used together under medical guidance.

With medications

  • CautionSystemic administration of any kind — gramicidin is strictly for topical and ophthalmic use due to hemolytic toxicity — Use with caution—discuss with your healthcare provider.
  • CautionApplication to extensive burn wounds or large denuded skin areas — risk of systemic absorption and hemolysis — Use with caution—discuss with your healthcare provider.
  • CautionContact lens wear during ophthalmic treatment — remove lenses before applying gramicidin ophthalmic preparations — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Gramicidin. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs hours 0-24 (first application)

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Rapid

(hours to days)


How it works

Gramicidin is an antimicrobial peptide antibiotic that kills bacteria by punching holes in their cell membranes, used primarily in topical creams and ointments for treating skin infections.

The deeper mechanism

Gramicidin is a 15-amino acid linear peptide antibiotic produced by Bacillus brevis that forms voltage-gated ion channels (gramicidin A channels) in lipid bilayers through β6.3-helical dimeric structures.

These channels allow passage of small cations (K+, Na+, H+) across bacterial membranes, depolarizing the membrane potential and disrupting ion gradients essential for bacterial survival.

Gramicidin exhibits rapid bactericidal activity against Gram-positive bacteria including Bacillus, Corynebacterium, Clostridium, and Staphylococcus species, with minimal systemic absorption when applied topically.


What to expect

  1. Hours 0-24 (first application)

    What you might notice

    • Mild stinging or burning at application site (1-2 minutes)
    • Antimicrobial action begins within minutes of application
    • For conjunctivitis: beginning of symptom relief (less discharge, reduced redness)
    • For wounds: antimicrobial barrier established at wound surface

    What's normal

    • Gramicidin channels form within milliseconds — antimicrobial activity is essentially immediate at the site
    • Mild stinging is normal and brief with ophthalmic preparations
    • Significant clinical improvement typically takes 24-48 hours to become apparent
    • Wound applications prevent secondary infection while healing begins

    What's next

    • Continue regular application schedule (3-4x daily ophthalmic, 2-3x daily topical)
    • Clinical improvement expected by day 2-3 for conjunctivitis
    • Maintain wound cleanliness between applications
    • Monitor for any worsening or signs of allergic reaction
  2. Days 2-5 (active treatment)

    What you might notice

    • Significant improvement in conjunctivitis symptoms (reduced discharge, decreasing redness, less discomfort)
    • Wound healing progressing with reduced infection signs
    • Possible mild allergic sensitization in susceptible individuals
    • Overall improvement in treated condition

    What's normal

    • Most bacterial conjunctivitis cases respond within 3-5 days of topical antibiotic treatment
    • Superficial wound infections improve within 3-7 days with topical antibiotics
    • Combination preparations (gramicidin + polymyxin B + neomycin) provide broad-spectrum coverage
    • If no improvement by day 3, consider reassessment and alternative therapy

    What's next

    • Complete the full prescribed course (typically 7-10 days)
    • If conjunctivitis resolved by day 5, may discontinue per physician guidance
    • Do not exceed 10 days without medical reassessment
    • Transition to standard wound care once infection is controlled
  3. Days 5-10 (completion)

    What you might notice

    • Infection resolved in most cases
    • Eye returns to normal appearance (conjunctivitis)
    • Wound healing well with no signs of infection
    • Treatment course completed

    What's normal

    • Most superficial bacterial infections resolve within 7-10 days of topical treatment
    • No resistance development expected with short topical courses
    • Post-treatment recurrence is uncommon for simple infections
    • Continued wound care (cleaning, protection) after antibiotic completion

    What's next

    • Discontinue gramicidin-containing product at end of treatment course
    • Monitor for any recurrence of symptoms
    • If symptoms persist beyond 10 days, seek medical evaluation for possible resistant organism or alternative diagnosis
    • Resume normal eye care or wound management

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Gramicidin over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

Why can't gramicidin be taken orally or given as an injection?

Gramicidin forms ion channels in any biological membrane it contacts — not just bacterial membranes. When exposed to human red blood cells, gramicidin channels cause rapid K⁺ loss and Na⁺ influx, leading to osmotic swelling and hemolysis (rupture of red blood cells). At systemic concentrations needed for antimicrobial efficacy, massive hemolysis would occur. This hemolytic toxicity makes any systemic route (IV, IM, oral for systemic effect) dangerous. Topical and ophthalmic use is safe because minimal amounts are absorbed into the bloodstream.

Was gramicidin really the first antibiotic?

Gramicidin was the first antimicrobial substance to be commercially manufactured and clinically tested in humans — predating the widespread clinical availability of penicillin. René Dubos discovered it in 1939 at Rockefeller University by isolating antimicrobial compounds from the soil bacterium Brevibacillus brevis. While Alexander Fleming discovered penicillin in 1928, it wasn't until 1941-1942 that penicillin was developed for clinical use. Gramicidin was used topically for wound infections during World War II. Its discovery proved that soil organisms produce antimicrobial substances, directly inspiring Selman Waksman's search that led to streptomycin.

What makes gramicidin's structure so unusual?

Gramicidin A has one of the most unusual structures in biology — its 15 amino acids alternate between D- and L-configurations (D-amino acids are rare in nature). This alternating stereochemistry prevents the peptide from folding into common structures like alpha-helices or beta-sheets. Instead, it forms a unique β⁶·³ helix — a single-stranded helix with 6.3 residues per turn. Two of these helices dimerize head-to-head within the membrane to form a transmembrane channel exactly the right length to span a lipid bilayer.

Is the gramicidin in Neosporin safe?

Yes, gramicidin in topical and ophthalmic preparations like Neosporin is safe when used as directed. The concentrations are low (0.025 mg/mL in ophthalmic solution), systemic absorption through intact skin or eye is minimal, and these products have decades of safe clinical use. The hemolytic toxicity that prevents systemic use only occurs when gramicidin reaches significant concentrations in the bloodstream, which does not happen with normal topical application to small wound areas.

Why is gramicidin so important for scientific research?

Gramicidin channels are the most extensively studied ion channels in all of biophysics. Their small size (just two peptides forming one channel), defined structure, and predictable conductance properties make them ideal model systems for understanding how ions cross biological membranes. Gramicidin channels have been used to develop the theory of ion channel conductance, validate computational molecular dynamics simulations, understand membrane thickness effects on channel function, and develop single-channel electrophysiology techniques. Over 10,000 research papers have been published on gramicidin channels.

Can gramicidin treat MRSA infections?

Gramicidin has in vitro activity against MRSA (methicillin-resistant Staphylococcus aureus) because its ion channel mechanism is independent of the penicillin-binding protein modifications that confer methicillin resistance. However, gramicidin can only be used topically — for superficial MRSA skin infections, topical gramicidin-containing preparations may provide some benefit, but mupirocin or retapamulin are preferred topical agents for MRSA. Serious or deep MRSA infections require systemic antibiotics (vancomycin, daptomycin, linezolid) that gramicidin cannot replace.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Gramicidin, on one page.

Gramicidin dosing protocol

Medical disclaimer

Gramicidin is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

0.025 mg Every 4 hours (up to 2 drops every hour for severe infection) · onset hours to days
Open the Gramicidin calculatorGramicidin calculator